Mark Levin Steps Down As CEO Of Millennium

June 30, 2005 -- Mark Levin, the legendary deal maker of the genomics era, is calling it quits. Like Haseltine, Venter, Hunkapillar and other famous genomics-era CEOs before him, Levin is making room for someone with more experience in drug development. Levin was a co-founder of Millennium, serving as its CEO for 12 years. He became famous for his "over the top deals"--collaborative R&D agreements with pharma of ever-increasing scope and size. Each time analysts put caps on potential revenue income from deals, Millennium signed a deal of substantially larger size, raising the bar again. We look at the history of those deals and the position in which Millennium now finds itself...

Back to news